Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A.,
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to produce or generate Real-World Evidence (RWE), thereby working toward a set of “international standards”.
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.,
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.
Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market shares of a drug? Understanding the answers to these questions can be crucial when conducting cost-effectiveness analyses i.e. when studying if it is desirable to publicly fund reimburse a new drug. This paper models and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations.
It is often argued that the demands for increased healthcare expenditure arising from an ageing population, advancing technologies, and increasing expectations, warrant higher healthcare budgets. Professor Stephen Birch argues that this reactive approach is not sustainable, and that the perceived mismatch between resources and demand is due to poor health service planning. In this briefing, based on an OHE lunchtime seminar, Professor Birch presents a framework to re-focus planning models on population needs.
The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.
Hernandez-Villafuerte, K., Li, R., Towse, A. and Chalkidou, K.
This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa, Uganda, China, India, Indonesia, Myanmar, Philippines, Thailand and Vietnam).